Skip to main content
TipRanks
Go Ultimate75% OFF

Ligand Pharma (LGND) Stock Statistics & Valuation Metrics

860 Followers

Total Valuation

Ligand Pharma has a market cap or net worth of $6.04B. The enterprise value is $6.94B.

Market Cap
$6.04B
Enterprise Value
$6.94B

Share Statistics

Ligand Pharma has 20,002,987 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
20,002,987
Owned by Insiders
2.46%
Owned by Institutions
94.64%

Financial Efficiency

Ligand Pharma’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 2.42%.

Return on Equity (ROE)
0.12
Return on Assets (ROA)
0.08
Return on Invested Capital (ROIC)
2.42%
Return on Capital Employed (ROCE)
0.03
Revenue Per Employee
5.70M
Profits Per Employee
2.65M
Employee Count
47
Asset Turnover
0.17
Inventory Turnover
0.72

Valuation Ratios

The current PE Ratio of Ligand Pharma is 116.73. Ligand Pharma’s PEG ratio is 13.95.

PE Ratio
116.73
PS Ratio
23.82
PB Ratio
6.27
Price to FCF
66.78
Price to Operating Cash Flow
66.35
PEG Ratio
13.95

Income Statement

In the last 12 months, Ligand Pharma had revenue of 268.09M and earned 124.45M in profits. Earnings per share was 6.44.

Revenue
268.09M
Gross Profit
261.50M
Operating Income
47.20M
Pretax Income
158.96M
Net Income
124.45M
EBITDA
192.74M
Earnings Per Share (EPS)
6.44

Cash Flow

In the last 12 months, operating cash flow was 90.96M and capital expenditures -405,000, giving a free cash flow of 90.56M billion.

Operating Cash Flow
90.96M
Free Cash Flow
90.56M
Free Cash Flow per Share
4.54

Dividends & Yields

Ligand Pharma pays an annual dividend of $0.46, resulting in a dividend yield of ―

Dividend Per Share
$0.46
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
1.50%
Earnings Yield
0.85%

Stock Price Statistics

Beta
0.89
52-Week Price Change
50.21%
50-Day Moving Average
301.71
200-Day Moving Average
259.38
Relative Strength Index (RSI)
50.19
Average Volume (3m)
225.76K

Important Dates

Ligand Pharma upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).

Last Earnings Date
Oct 29, 2026
Next Earnings Date
Mar 04, 2027
Ex-Dividend Date
Jul 02, 2010

Financial Position

Ligand Pharma as a current ratio of 22.23, with Debt / Equity ratio of 44.39%

Current Ratio
22.23
Quick Ratio
21.98
Debt to Market Cap
0.12
Net Debt to EBITDA
1.43
Interest Coverage Ratio
10.01

Taxes

In the past 12 months, Ligand Pharma has paid 34.51M in taxes.

Income Tax
34.51M
Effective Tax Rate
0.22

Enterprise Valuation

Ligand Pharma EV to EBITDA ratio is 88.58, with an EV/FCF ratio of 78.78.

EV to Sales
28.11
EV to EBITDA
88.58
EV to Free Cash Flow
78.78
EV to Operating Cash Flow
78.43

Balance Sheet

Ligand Pharma has $447.39M in cash and marketable securities with $1.15B in debt, giving a net cash position of -$706.81M billion.

Cash & Marketable Securities
$447.39M
Total Debt
$1.15B
Net Cash
-$706.81M
Net Cash Per Share
-$35.34
Tangible Book Value Per Share
$22.64

Margins

Gross margin is 107.11%, with operating margin of 11.91%, and net profit margin of 20.27%.

Gross Margin
107.11%
Operating Margin
11.91%
Pretax Margin
20.77%
Net Profit Margin
20.27%
EBITDA Margin
31.73%
EBIT Margin
21.46%

Analyst Forecast

The average price target for Ligand Pharma is $364.88, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$364.88
Price Target Upside
20.94% Upside
Analyst Consensus
Strong Buy
Analyst Count
9
Revenue Growth Forecast
1.03%
EPS Growth Forecast
8.35%

Scores

Smart Score
8
AI Score
68